Arch Biopartners Inc(ACHFF)

Description: Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. The company develops AB569, a drug candidate for the treatment of antibiotic resistant lung and urinary tract bacterial infections, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. It also develops MetaBlok, a drug candidate for the treatment of sepsis, cancer metastasis, and inflammation based diseases, as well as in a phase I safety trial for treating acute kidney injury; and Arch inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada.

---

Keywords: Biotechnology Cancer Inflammation E Health Bacteria Bacteriology Kidney Fibrosis Brain Tumor Cystic Fibrosis Bacterial Infections Sepsis Molecules Biofilm Mx Chronic Kidney Pathogenic Bacteria Glioma Acute Kidney Injury Metastasis Cyst Gram Negative Bacteria Pseudomonas Pseudomonas Aeruginosa Respiratory Tract Bacterial Infection Bowel Diseases Kidney Injury Pseudomonadales Ab569 Arch Inflammation Cancer Metastasis Invasive Glioma Non Infectious Inflammation Treatment Of Sepsis

---

Home Page: www.archbiopartners.com

27 Street Clair Avenue East
Toronto, ON M4T 2M5
Canada
Phone: 647 428 7031

---

Officers

Exchange: OTCQB

Country: US

Currency: US Dollar ($)